Corneal Toxicity Induced by ABT-414 Therapy for Glioblastoma Multiforme: A Case Report

Corneal Toxicity Induced by ABT-414 Therapy for Glioblastoma Multiforme: A Case Report

BACKGROUNDTo describe a case of corneal toxicity associated with the use of the epidermal growth factor receptor (EGFR) inhibitor ABT-414 in the treatment of glioblastoma multiforme. CASE PRESENTATIONCase report of a 56-year-old male with glioblastoma multiforme who developed mild painless blurred v...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Case reports in ophthalmology 2018, Vol.9 (3), p.479-483
Hauptverfasser: Eshraghi, Hamoon, Mantopoulos, Dimosthenis, Suh, Leejee H, Zaldana, Francisco, Fine, Howard F
Format: Report
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 483
container_issue 3
container_start_page 479
container_title Case reports in ophthalmology
container_volume 9
creator Eshraghi, Hamoon
Mantopoulos, Dimosthenis
Suh, Leejee H
Zaldana, Francisco
Fine, Howard F
description BACKGROUNDTo describe a case of corneal toxicity associated with the use of the epidermal growth factor receptor (EGFR) inhibitor ABT-414 in the treatment of glioblastoma multiforme. CASE PRESENTATIONCase report of a 56-year-old male with glioblastoma multiforme who developed mild painless blurred vision after systemic treatment with the investigational EGFR inhibitor ABT-414. The patient had best corrected visual acuity of 20/60 right eye and 20/50 left eye. Ophthalmic examination revealed corneal toxicity with whorl-like opacities in the inferior interpalpebral cornea. The patient was treated with topical fluoromethalone and lifitegrast, and his ocular symptoms as well as the corneal findings improved. CONCLUSIONSThe systemic use of EGFR inhibitor ABT-414 may be associated with corneal toxicity and the effects are reversible with treatment.
doi_str_mv 10.1159/000494713
format Report
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_miscellaneous_2179338638</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2179338638</sourcerecordid><originalsourceid>FETCH-proquest_miscellaneous_21793386383</originalsourceid><addsrcrecordid>eNqVir0KwjAYAIMoKOrgG3yjSzVpam3ctPg3uEhxlVg_MZI2NUnBvr0ODq5OdxxHyIjRCWMzMaWURiKaM94iPRbHPAhjIdo_3iVD5x6fjXIRJmzWI6fU2BKlhsy8VK58A_vyWud4hUsDy1UWRCyC7I5WVg3cjIWtVuaipfOmkHCotVefWuAClpBKh3DEylg_IJ2b1A6HX_bJeLPO0l1QWfOs0flzoVyOWssSTe3OIZsLzpOYJ_yP9Q3JMUkB</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>report</recordtype><pqid>2179338638</pqid></control><display><type>report</type><title>Corneal Toxicity Induced by ABT-414 Therapy for Glioblastoma Multiforme: A Case Report</title><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Karger Open Access</source><creator>Eshraghi, Hamoon ; Mantopoulos, Dimosthenis ; Suh, Leejee H ; Zaldana, Francisco ; Fine, Howard F</creator><creatorcontrib>Eshraghi, Hamoon ; Mantopoulos, Dimosthenis ; Suh, Leejee H ; Zaldana, Francisco ; Fine, Howard F</creatorcontrib><description>BACKGROUNDTo describe a case of corneal toxicity associated with the use of the epidermal growth factor receptor (EGFR) inhibitor ABT-414 in the treatment of glioblastoma multiforme. CASE PRESENTATIONCase report of a 56-year-old male with glioblastoma multiforme who developed mild painless blurred vision after systemic treatment with the investigational EGFR inhibitor ABT-414. The patient had best corrected visual acuity of 20/60 right eye and 20/50 left eye. Ophthalmic examination revealed corneal toxicity with whorl-like opacities in the inferior interpalpebral cornea. The patient was treated with topical fluoromethalone and lifitegrast, and his ocular symptoms as well as the corneal findings improved. CONCLUSIONSThe systemic use of EGFR inhibitor ABT-414 may be associated with corneal toxicity and the effects are reversible with treatment.</description><identifier>ISSN: 1663-2699</identifier><identifier>EISSN: 1663-2699</identifier><identifier>DOI: 10.1159/000494713</identifier><language>eng</language><ispartof>Case reports in ophthalmology, 2018, Vol.9 (3), p.479-483</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>776,780,860,4476,27902</link.rule.ids></links><search><creatorcontrib>Eshraghi, Hamoon</creatorcontrib><creatorcontrib>Mantopoulos, Dimosthenis</creatorcontrib><creatorcontrib>Suh, Leejee H</creatorcontrib><creatorcontrib>Zaldana, Francisco</creatorcontrib><creatorcontrib>Fine, Howard F</creatorcontrib><title>Corneal Toxicity Induced by ABT-414 Therapy for Glioblastoma Multiforme: A Case Report</title><title>Case reports in ophthalmology</title><description>BACKGROUNDTo describe a case of corneal toxicity associated with the use of the epidermal growth factor receptor (EGFR) inhibitor ABT-414 in the treatment of glioblastoma multiforme. CASE PRESENTATIONCase report of a 56-year-old male with glioblastoma multiforme who developed mild painless blurred vision after systemic treatment with the investigational EGFR inhibitor ABT-414. The patient had best corrected visual acuity of 20/60 right eye and 20/50 left eye. Ophthalmic examination revealed corneal toxicity with whorl-like opacities in the inferior interpalpebral cornea. The patient was treated with topical fluoromethalone and lifitegrast, and his ocular symptoms as well as the corneal findings improved. CONCLUSIONSThe systemic use of EGFR inhibitor ABT-414 may be associated with corneal toxicity and the effects are reversible with treatment.</description><issn>1663-2699</issn><issn>1663-2699</issn><fulltext>true</fulltext><rsrctype>report</rsrctype><creationdate>2018</creationdate><recordtype>report</recordtype><recordid>eNqVir0KwjAYAIMoKOrgG3yjSzVpam3ctPg3uEhxlVg_MZI2NUnBvr0ODq5OdxxHyIjRCWMzMaWURiKaM94iPRbHPAhjIdo_3iVD5x6fjXIRJmzWI6fU2BKlhsy8VK58A_vyWud4hUsDy1UWRCyC7I5WVg3cjIWtVuaipfOmkHCotVefWuAClpBKh3DEylg_IJ2b1A6HX_bJeLPO0l1QWfOs0flzoVyOWssSTe3OIZsLzpOYJ_yP9Q3JMUkB</recordid><startdate>20180901</startdate><enddate>20180901</enddate><creator>Eshraghi, Hamoon</creator><creator>Mantopoulos, Dimosthenis</creator><creator>Suh, Leejee H</creator><creator>Zaldana, Francisco</creator><creator>Fine, Howard F</creator><scope>7X8</scope></search><sort><creationdate>20180901</creationdate><title>Corneal Toxicity Induced by ABT-414 Therapy for Glioblastoma Multiforme: A Case Report</title><author>Eshraghi, Hamoon ; Mantopoulos, Dimosthenis ; Suh, Leejee H ; Zaldana, Francisco ; Fine, Howard F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_miscellaneous_21793386383</frbrgroupid><rsrctype>reports</rsrctype><prefilter>reports</prefilter><language>eng</language><creationdate>2018</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Eshraghi, Hamoon</creatorcontrib><creatorcontrib>Mantopoulos, Dimosthenis</creatorcontrib><creatorcontrib>Suh, Leejee H</creatorcontrib><creatorcontrib>Zaldana, Francisco</creatorcontrib><creatorcontrib>Fine, Howard F</creatorcontrib><collection>MEDLINE - Academic</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Eshraghi, Hamoon</au><au>Mantopoulos, Dimosthenis</au><au>Suh, Leejee H</au><au>Zaldana, Francisco</au><au>Fine, Howard F</au><format>book</format><genre>unknown</genre><ristype>RPRT</ristype><atitle>Corneal Toxicity Induced by ABT-414 Therapy for Glioblastoma Multiforme: A Case Report</atitle><jtitle>Case reports in ophthalmology</jtitle><date>2018-09-01</date><risdate>2018</risdate><volume>9</volume><issue>3</issue><spage>479</spage><epage>483</epage><pages>479-483</pages><issn>1663-2699</issn><eissn>1663-2699</eissn><abstract>BACKGROUNDTo describe a case of corneal toxicity associated with the use of the epidermal growth factor receptor (EGFR) inhibitor ABT-414 in the treatment of glioblastoma multiforme. CASE PRESENTATIONCase report of a 56-year-old male with glioblastoma multiforme who developed mild painless blurred vision after systemic treatment with the investigational EGFR inhibitor ABT-414. The patient had best corrected visual acuity of 20/60 right eye and 20/50 left eye. Ophthalmic examination revealed corneal toxicity with whorl-like opacities in the inferior interpalpebral cornea. The patient was treated with topical fluoromethalone and lifitegrast, and his ocular symptoms as well as the corneal findings improved. CONCLUSIONSThe systemic use of EGFR inhibitor ABT-414 may be associated with corneal toxicity and the effects are reversible with treatment.</abstract><doi>10.1159/000494713</doi></addata></record>
fulltext fulltext
identifier ISSN: 1663-2699
ispartof Case reports in ophthalmology, 2018, Vol.9 (3), p.479-483
issn 1663-2699
1663-2699
language eng
recordid cdi_proquest_miscellaneous_2179338638
source DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Karger Open Access
title Corneal Toxicity Induced by ABT-414 Therapy for Glioblastoma Multiforme: A Case Report
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T20%3A45%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:book&rft.genre=unknown&rft.atitle=Corneal%20Toxicity%20Induced%20by%20ABT-414%20Therapy%20for%20Glioblastoma%20Multiforme:%20A%20Case%20Report&rft.jtitle=Case%20reports%20in%20ophthalmology&rft.au=Eshraghi,%20Hamoon&rft.date=2018-09-01&rft.volume=9&rft.issue=3&rft.spage=479&rft.epage=483&rft.pages=479-483&rft.issn=1663-2699&rft.eissn=1663-2699&rft_id=info:doi/10.1159/000494713&rft_dat=%3Cproquest%3E2179338638%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2179338638&rft_id=info:pmid/&rfr_iscdi=true